Search This Blog

Tuesday, April 2, 2024

IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System

  IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has filed a 510(k) submission with the United States Food and Drug Administration ("FDA") for clearance of its next-generation single probe cryoablation system, the XSense™ System and cryoprobes. The filing contains a request for clearance for all of the indications for which ProSense® has already received the requisite FDA clearance, including general minimally invasive cryoablation applications for the kidney, liver, fibroadenomas and neurology.

This new application for IceCure's next-generation single probe XSense™ with cryoprobes is based on the current clearance of the ProSense® System, and is being processed separately from the Company's De Novo application for the breast cancer indication.

https://www.biospace.com/article/releases/icecure-submits-fda-regulatory-filing-for-new-xsense-cryoablation-system-with-cryoprobes/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.